NAGE צמיחה צפויה ברווח נקי למניה השנה ChromaDex Corp.

Chromadex Corp controls the NAD+ market through exclusive patents on Niagen, ensuring stable demand. The YoY net income per share trend confirms the success of developing innovative anti-aging supplements, with the current level standing at -71.60. Simultaneously, the company is implementing sustainable supply chain controls and packaging recycling, adhering to modern industry safety standards.

To objectively assess the fundamental quality of Chromadex Corp (NAGE), investors must track the year-over-year dynamics of earnings per share. By analyzing the annual EPS change, one can promptly identify net income growth rates, which for this company confirms the effectiveness of patent protection for unique biocomponents and the ability to maintain pricing power in the global market.